Gilead Sciences Gets Boost from Wall Street, Valuation Reassessed Amid HIV and Oncology Momentum

Gilead Sciences (GILD) receives a fresh Buy rating from Truist and a longer US exclusivity window for HIV flagship Biktarvy from Mizuho. The stock has a 36% year-to-date return and a 5-year total shareholder return above 150%. The combination of upbeat HIV and oncology commentary and a longer Biktarvy exclusivity window has supported sentiment, but the stock is near fresh highs and already at a modest discount to analyst targets.